BackCatalyst Pharmaceuticals Overview
Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Target Price

Analysts' average 12-month price target for Catalyst Pharmaceuticals is $32.

Get informed when a big investor buys or sells

+ Follow

Share Price

$31.49

Average Target Price

$31.500% upside

1 analysts in the last 4 months

High: $31.5 | Low: $31.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-28H.C. Wainwright$31.50% upsideOpen
2026-05-07Stephens$321.6% upsideOpen
2025-11-07OppenheimerLeland Gershell$334.8% upsideOpen
2025-03-03Robert W. Baird$321.6% upsideOpen
2025-02-04Robert W. BairdJoel Beatty$2811.1% downsideOpen
2025-01-10H.C. WainwrightAndrew Fein$3511.1% upsideOpen
2022-12-21Truist Financial$1842.8% downsideOpen
2022-12-21H.C. Wainwright$2423.8% downsideOpen
2022-12-19Piper SandlerJoseph Catanzaro$2036.5% downsideOpen
2022-08-24Roth CapitalScott Henry$15.550.8% downsideOpen
2022-08-11Truist Financial$1746% downsideOpen
2022-08-11H.C. Wainwright$1842.8% downsideOpen

Catalyst Pharmaceuticals (CPRX) FAQ

Catalyst Pharmaceuticals (CPRX) currently reports a target price of $32. Use the charts on this page to explore Catalyst Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Catalyst Pharmaceuticals is $32, about 0.0% upside from the current share price of $31.49. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $32, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Catalyst Pharmaceuticals, and consider following CPRX for alerts when major investors trade the stock.

Catalyst Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $32. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CPRX with unrelated industries.